#1 Clinical Trials Search in Europe

Palmidrol

Palmidrol, also known as palmitoylethanolamide (PEA), is a naturally occurring fatty acid amide that has been the subject of numerous clinical trials investigating its potential therapeutic benefits. This article provides an overview of recent studies exploring the use of PEA in various medical conditions, including chronic pain, neuropathy, depression, and inflammatory disorders. We’ll examine the current research, potential applications, and what these trials reveal about PEA’s efficacy and safety profile.

Table of Contents

What is PALMIDROL?

PALMIDROL, also known as Palmitoylethanolamide (PEA), is a naturally occurring fatty acid amide that has gained attention for its potential therapeutic properties[3]. It is an endogenous compound, meaning it is produced naturally in the body, and is part of a class of molecules called N-acylethanolamines (NAEs)[4]. PEA is found in various foods such as peanuts, egg yolks, and soybeans[5].

PALMIDROL is known by several other names, including:

  • N-Palmitoyl Ethanolamide
  • N-Palmitoylethanolamide
  • Palmitoyl Ethanolamide
  • Palmitoylethanolamide
  • PEA

How PALMIDROL Works

PALMIDROL works in several ways to help reduce pain and inflammation in the body:

  1. Anti-inflammatory effects: PEA modulates immune responses, inhibits mast cell activation (cells involved in allergic and inflammatory responses), and reduces the release of pro-inflammatory substances called cytokines[3].
  2. Pain reduction: PEA interacts with various receptors and channels in the body, including PPAR-α (peroxisome proliferator-activated receptor alpha), TRPV1 channels, and GPR55 receptors. These interactions help to reduce pain signals[3].
  3. Neuroprotection: Some studies suggest that PEA may have protective effects on nerve cells, which could be beneficial in conditions affecting the nervous system[6].

Conditions Treated with PALMIDROL

Research suggests that PALMIDROL may be beneficial for various health conditions, including:

  • Chronic pain: Studies have shown potential benefits in treating different types of chronic pain, including neuropathic pain (pain caused by nerve damage) and inflammatory pain[1][3].
  • Chemotherapy-induced peripheral neuropathy: This is a nerve problem causing pain, numbness, tingling, or muscle weakness in different parts of the body due to chemotherapy treatment[1].
  • Depression: Some research is exploring the use of PEA for major depression, including both unipolar and bipolar depression[2].
  • Tourette Syndrome: PEA is being studied in combination with other compounds for the treatment of Tourette Syndrome, a disorder characterized by repetitive, involuntary movements and vocalizations[7].
  • Endometriosis and chronic pelvic pain: PEA has shown promise in reducing pain associated with endometriosis, a condition where tissue similar to the lining of the uterus grows outside the uterus[4].
  • Amyotrophic Lateral Sclerosis (ALS): Research is ongoing to determine if PEA can help with symptoms of ALS, a progressive nervous system disease that affects nerve cells in the brain and spinal cord[6].
  • Eczema: Topical formulations of PEA are being studied for their potential to reduce symptoms of eczema, a condition causing dry, itchy, and inflamed skin[8].

Dosage and Administration

The dosage and administration of PALMIDROL can vary depending on the condition being treated and the specific formulation used. Some common dosages observed in clinical trials include:

  • 600 mg twice daily (1200 mg total per day) for various pain conditions[1][3]
  • 300 mg to 1200 mg daily for depression[2]
  • Topical application for skin conditions like eczema[8]

PALMIDROL is available in various forms, including oral capsules, tablets, and topical creams. Always follow the dosage instructions provided by your healthcare provider or as indicated on the product label.

Safety and Side Effects

PALMIDROL is generally considered safe and well-tolerated. Clinical trials have reported minimal side effects, making it a potentially attractive option for long-term use in chronic pain management[3]. However, as with any supplement or medication, it’s important to consult with a healthcare professional before starting use, especially if you have any existing health conditions or are taking other medications.

Ongoing Research

Several clinical trials are currently underway to further investigate the potential benefits of PALMIDROL for various conditions. These studies aim to provide more concrete evidence on its efficacy and optimal use. Some areas of ongoing research include:

  • Combination therapy with other compounds for enhanced effects[7]
  • Use in opioid use disorder to reduce cravings and manage pain[5]
  • Potential neuroprotective effects in conditions like ALS[6]

As research continues, we may gain a better understanding of how PALMIDROL can be used effectively in various health conditions. If you’re considering using PALMIDROL, it’s important to discuss it with your healthcare provider to determine if it’s appropriate for your specific situation.

Aspect Details
Main Compound Palmidrol (Palmitoylethanolamide, PEA)
Conditions Studied Chemotherapy-induced neuropathy, Major depression, Chronic pain, Tourette syndrome, Opioid use disorder, Endometriosis-related pain, ALS
Common Dosages 600-1200 mg/day, often divided into two doses
Administration Oral capsules or tablets, sometimes micronized or ultra-micronized
Mechanism of Action Activates PPAR-α, modulates inflammation and pain pathways
Safety Profile Generally well-tolerated with minimal reported side effects
Trial Designs Randomized controlled trials, N-of-1 trials, open-label studies
Outcome Measures Pain scales, quality of life assessments, functional status, biomarkers
Potential Benefits Pain reduction, improved function, decreased inflammation, potential neuroprotection
Research Status Ongoing clinical trials in various phases, from pilot studies to larger efficacy trials

FAQ

  • What is Palmidrol (PEA) and how does it work? Palmidrol, or palmitoylethanolamide (PEA), is an endogenous fatty acid amide that acts on various cellular pathways involved in pain modulation and inflammation. It primarily works by activating peroxisome proliferator-activated receptor alpha (PPAR-α) and influencing other mechanisms related to neuroinflammation and immune responses.
  • What medical conditions are being studied with PEA in clinical trials? Clinical trials are investigating PEA for a wide range of conditions, including chemotherapy-induced peripheral neuropathy, major depression, chronic pain, Tourette syndrome, opioid use disorder, and endometriosis-related pelvic pain. Some studies are also exploring its potential in amyotrophic lateral sclerosis (ALS).
  • What are the typical dosages of PEA used in clinical trials? Dosages of PEA in clinical trials vary, but common ranges include 600 mg to 1200 mg per day, often divided into two daily doses. For example, some studies use 600 mg twice daily, while others may use 400 mg twice daily. The specific dosage depends on the condition being studied and the trial design.
  • Are there any known side effects of PEA? PEA is generally reported to have a favorable safety profile with minimal side effects. Most clinical trials describe it as well-tolerated. However, as with any medication or supplement, individual responses may vary, and more research is needed to fully understand its long-term safety profile.
  • How is PEA administered in clinical trials? In most clinical trials, PEA is administered orally in the form of capsules or tablets. Some studies use micronized or ultra-micronized formulations to potentially improve absorption. In certain trials, it may be combined with other compounds, such as polydatin, or used in conjunction with standard treatments for the condition being studied.

Ongoing Clinical Trials on Palmidrol

  • Study on the Effects of Dronabinol and Palmidrol for Adults with Tourette Syndrome

    Recruiting

    1
    Investigated drugs:
    Germany

Glossary

  • Palmitoylethanolamide (PEA): An endogenous fatty acid amide that has anti-inflammatory and pain-relieving properties. It is being studied for various medical conditions and is available as a dietary supplement in some countries.
  • Chemotherapy-Induced Peripheral Neuropathy (CIPN): A nerve problem causing pain, numbness, tingling, or muscle weakness in different parts of the body, resulting from chemotherapy treatment.
  • Major Depressive Episode (MDE): A period characterized by persistent depressed mood or loss of interest in activities, causing significant impairment in daily life.
  • Peroxisome Proliferator-Activated Receptor Alpha (PPAR-α): A nuclear receptor protein that plays a crucial role in regulating cellular metabolism and inflammation. PEA activates this receptor as part of its mechanism of action.
  • N-of-1 Trial: A clinical trial design where a single patient is the entire trial, receiving different treatments in a random order to determine which treatment works best for that individual.
  • Visual Analog Scale (VAS): A measurement instrument used to assess subjective characteristics or attitudes that cannot be directly measured, often used for pain assessment.
  • Amyotrophic Lateral Sclerosis (ALS): A progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control.
  • Acetylcholine Receptors (AChRs): Proteins in nerve cells that respond to the neurotransmitter acetylcholine, playing a crucial role in neuromuscular function.
  • Endocannabinoid: A naturally occurring compound in the body that interacts with the endocannabinoid system, involved in various physiological processes including pain sensation and inflammation.
  • Micronized/Ultra-micronized: A process of reducing the particle size of a substance to improve its absorption and bioavailability in the body.

References

  1. https://clinicaltrials.gov/study/NCT05246670
  2. https://clinicaltrials.gov/study/NCT06063369
  3. https://clinicaltrials.gov/study/NCT06273462
  4. https://clinicaltrials.gov/study/NCT02372903
  5. https://clinicaltrials.gov/study/NCT05480072
  6. https://clinicaltrials.gov/study/NCT02645461
  7. https://clinicaltrials.gov/study/NCT03066193
  8. https://clinicaltrials.gov/study/NCT05003453